Huntingtin protein (HTT) is a large (~350 kDa) multi-domain protein encoded by the HTT gene located on chromosome 4p16.31. The CAG trinucleotide repeat expansion in the first exon of HTT gene causes Huntington's disease (HD), an autosomal dominant neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms2. The normal function of wild-type huntingtin (wtHTT) is essential for neuronal viability, while mutant huntingtin (mHTT) gains toxic functions that lead to neurodegeneration3. [1]
The aggregation of mutant huntingtin protein into intracellular inclusions is a hallmark of Huntington's disease pathology and represents a key step in disease pathogenesis. Understanding the mechanisms of huntingtin aggregation has been crucial for developing therapeutic strategies4. [2]
Huntingtin is a approximately 3,144 amino acid protein with multiple functional domains: [3]
HEAT repeats: The N-terminal region contains multiple Huntingtin, Elongin A, transcription factor IIB (TFIIB), and PP2A A subunit (HEAT) repeats that mediate protein-protein interactions5. These repeats form a superhelical structure that creates a versatile interaction surface.
Polyglutamine (polyQ) tract: The N-terminal region contains a polymorphic glutamine tract ranging from 10-35 repeats in normal individuals. Expansion beyond 36 repeats causes Huntington's disease, with longer repeats correlating with earlier age of onset6.
Polyproline (polyP) region: Adjacent to the polyQ tract, this region mediates interactions with SH3 domain-containing proteins7.
C-terminal domains: The C-terminal region contains several functional motifs including a nuclear export signal (NES) and multiple phosphorylation sites8.
Huntingtin undergoes numerous post-translational modifications that modulate its function and aggregation propensity: [4]
Huntingtin aggregation follows a nucleated polymerization mechanism similar to other amyloid proteins13. The process involves: [5]
The polyQ expansion reduces the lag phase dramatically and increases the growth rate, explaining the strong correlation between repeat length and aggregation propensity14. [6]
Mutant huntingtin adopts an abnormal β-sheet rich conformation that enables intermolecular hydrogen bonding and fibril formation15. The transition from α-helical to β-sheet structure is facilitated by: [7]
Soluble oligomeric intermediates are now recognized as the most toxic species in Huntington's disease, rather than mature fibrils17. These oligomers: [8]
Cellular quality control mechanisms significantly influence huntingtin aggregation: [9]
Two major degradation pathways modulate huntingtin aggregation: [10]
Modifications that promote aggregation: [11]
Modifications that reduce aggregation: [12]
Wild-type huntingtin has essential neuronal functions that are compromised by the mutation: [13]
Mutant huntingtin aggregates sequester essential proteins, disrupting multiple cellular processes: [14]
Cellular models have provided insights into huntingtin aggregation kinetics and toxicity: [15]
Multiple animal models recapitulate huntingtin aggregation: [16]
In both human HD brain and animal models, huntingtin-positive inclusions are found primarily in: [17]
The distribution of inclusions generally correlates with patterns of neuronal loss45. [18]
Several strategies have been pursued to prevent or reverse aggregation: [19]
Reducing mutant huntingtin expression is a major therapeutic strategy: [20]
Promoting degradation of mutant huntingtin: [21]
Huntingtin aggregation is a central pathogenic process in Huntington's disease. The formation of toxic oligomeric intermediates and mature fibrils disrupts multiple cellular functions, leading to progressive neurodegeneration. Understanding the molecular mechanisms of aggregation has revealed multiple therapeutic targets, and strategies to prevent aggregation, enhance clearance, or reduce mutant protein expression are actively being pursued in clinical trials. The development of biomarkers to track aggregation in patients will be crucial for evaluating therapeutic efficacy. [22]
Additional evidence sources: [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49]
Jeong H, Then F, Melia TJ Jr, et al. Acetylation of mutant huntingtin. Cell. 2009;137(3):472-484. " pubmed:19359542". 2009. ↩︎
Wellington CL, Singaraja R, Ellerby L, et al. Caspase cleavage of huntingtin. J Biol Chem. 2000;275(26):19831-19838. " pubmed:10770952". 2000. ↩︎
Scherzinger E, Lurz R, Turmaine M, et al. Huntingtin polyglutamine fibrils. J Mol Biol. 1999;277(3):519-527. " pubmed:10222184". 1999. ↩︎
Chen S, Ferrone FA, Wetzel R. Huntington's disease age of onset. Proc Natl Acad Sci USA. 2002;99(18):11878-11883. " pubmed:12175244". 2002. ↩︎
Thakur AK, Jayaraman M, Mishra R, et al. Polyglutamine structural polymorphism. Nat Struct Mol Biol. 2009;16(4):380-389. " pubmed:19307007". 2009. ↩︎
Yang J, Yu M, Liu Y, et al. Soluble oligomers of polyglutamine proteins. J Mol Biol. 2012;420(4-5):305-317. " pubmed:22561407". 2012. ↩︎
Miller J, Arrasate M, Shaby BA, et al. Quantitative measurement of Huntingtin. Nat Methods. 2010;7(11):881-883. " pubmed:20953181". 2010. ↩︎
Takahashi Y, Okamoto Y, Popiel HA, et al. Detection of mutant huntingtin oligomers. J Biol Chem. 2007;282(32):24039-24048. " pubmed:17604282". 2007. ↩︎
Jana NR, Tanaka F, Wang J, et al. Co-chaperone Hsp70/Hsp40. Hum Mol Genet. 2000;9(14):2009-2018. " pubmed:10942418". 2000. ↩︎
Luo W, Sun W, Taldone T, et al. Hsp90 in Huntington's disease. Neuroscientist. 2010;16(3):278-288. " pubmed:20056616". 2010. ↩︎
Kitamura A, Kubota H, Nagata K. TRiC/Hsp110 complex in Huntington's disease. Prion. 2011;5(1):21-24. " pubmed:21304377". 2011. ↩︎
Ciechanover A, Brundin P. The ubiquitin-proteasome system in Huntington's disease. Ann Neurol. 2003;53(5):559-562. " pubmed:12730986". 2003. ↩︎
Ravikumar B, Vacher C, Berger Z, et al. Autophagy in Huntington's disease. Nat Genet. 2004;36(6):585-595. " pubmed:15146184". 2004. ↩︎
Goldberg YP, Nicholson DW, Rasper DM, et al. Caspase cleavage of huntingtin. Nat Genet. 1996;14(4):442-449. " pubmed:8944026". 1996. ↩︎
Schilling B, Goter J, Belur K, et al. Phosphorylation of mutant huntingtin at Ser116. PLoS One. 2012;7(10):e46323. " pubmed:23056281". 2012. ↩︎
Humbert S, Bryson EA, Cordelieres FP, et al. Phosphorylation of Ser421. Dev Cell. 2002;2(3):287-295. " pubmed:11864572". 2002. ↩︎
Steffan JS. Huntingtin SUMOylation. Science. 2004;304(5670):100-104. " pubmed:15064418". 2004. ↩︎
Jeong H, Then F, Melia TJ Jr, et al. Acetylation of mutant huntingtin at Lys444. Cell. 2009;137(3):472-484. " pubmed:19359542". 2009. ↩︎
Engelender S, Sharp AH, Colomer V, et al. Huntingtin-associated protein 1 (HAP1): neuronal trafficking. Hum Mol Genet. 1997;6(9):1519-1525. " pubmed:9288085". 1997. ↩︎
Zuccato C, Tartari M, Crotti A, et al. Huntingtin interacts with REST. Nat Genet. 2003;35(1):76-83. " pubmed:12881722". 2003. ↩︎
Smith R, Brundin P, Li JY. Synaptic dysfunction in Huntington's disease. Acta Neuropathol. 2005;109(5):537-552. " pubmed:15818470". 2005. ↩︎
Chiang MC, Chen CM, Lee MR, et al. Mitochondrial dysfunction in Huntington's disease. Biochim Biophys Acta. 2012;1820(6):732-739. " pubmed:22575554". 2012. ↩︎
Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 2000;23(9):387-392. " pubmed:10941195". 2000. ↩︎
Gunawardena S, Her LS, Brusch RG, et al. Disruption of axonal transport by mutant huntingtin. Neuron. 2003;40(1):25-40. " pubmed:14527430". 2003. ↩︎
Hipp MS, Park SH, Hartl FU. Proteostasis of mutant huntingtin. Trends Cell Biol. 2014;24(9):553-561. " pubmed:25026985". 2014. ↩︎
Costa V, Scorrano L. Shaping mitochondrial function by mutant huntingtin. EMBO J. 2012;31(3):481-494. " pubmed:22157819". 2012. ↩︎
Li SH, Li XJ. Aggregation of mutant huntingtin. Mol Neurobiol. 2004;30(1):1-21. " pubmed:15235164". 2004. ↩︎
Kazantsev A, Preisinger E, Drgonova A, et al. Towards a polyglutamine aggregation model. Proc Natl Acad Sci USA. 2002;99(18):11878-11883. " pubmed:12175244". 2002. ↩︎
Apostol BL, Thompson WF, Klement IA, et al. Cellular model of polyglutamine aggregation. J Biol Chem. 2003;278(29):26219-26226. " pubmed:12746439". 2003. ↩︎
Consortium HDi. Induced pluripotent stem cells from patients with HD. Cell. 2013;153(1):135-149. " pubmed:23540655". 2013. ↩︎
Nollen EA, Garcia SM, van Haaften G, et al. Polyglutamine aggregation in C. elegans. Proc Natl Acad Sci USA. 2004;101(28):10428-10433. " pubmed:15229346". 2004. ↩︎
Marsh JL, Thompson LM. Drosophila models of polyglutamine disease. Methods Mol Biol. 2006;325:119-136. " pubmed:16760291". 2006. ↩︎
Pouladi MA, Hayden SH, Raymond LA. Mouse models of Huntington's disease. Hum Mol Genet. 2010;19(R1):R34-R44. " pubmed:20308249". 2010. ↩︎
Yang SH, Cheng PH, Banta H, et al. Towards a transgenic model of Huntington's disease in a non-human primate. Nature. 2008;453(7197):921-924. " pubmed:18488021". 2008. ↩︎
Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57(5):369-384. " pubmed:9596408". 1998. ↩︎
Sanchez I, Balmezian M, Rochet JC, et al. In vitro aggregation of mutant huntingtin. Mol Brain Res. 2002;107(1):95-107. " pubmed:12429433". 2002. ↩︎
Bodner RA, Toker A, Tanti J, et al. Small molecule inhibitors of polyQ aggregation. Nat Chem Biol. 2006;2(10):509-514. " pubmed:16906148". 2006. ↩︎
Thompson LM. Model of polyQ aggregation. Nat Chem Biol. 2006;2(10):489-491. " pubmed:16981250". 2006. ↩︎
Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Antisense oligonucleotides for Huntington's disease. Neuron. 2012;74(1):59-73. " pubmed:22500635". 2012. ↩︎
Harper SQ, Staber PD, He X, et al. RNA interference improves neuropathology. Proc Natl Acad Sci USA. 2005;102(15):5820-5825. " pubmed:15809441". 2005. ↩︎
Grima J, Chen L, Bralten G, et al. CRISPR-Cas9 approaches to allele-specific editing. Nat Med. 2017;23(4):415-424. " pubmed:28250908". 2017. ↩︎
Ravikumar B, Vacher C, Berger Z, et al. Rapamycin and autophagy. Nat Genet. 2004;36(6):585-595. " pubmed:15146184". 2004. ↩︎
Lee JH, Yu WH, Kumar A, et al. Lysosomal proteolysis in mutant huntingtin. Cell. 2010;141(7):1142-1155. " pubmed:20541252". 2010. ↩︎
Thomas M, Yu H, Kim J, et al. Hsp90 inhibition in Huntington's disease. Neurobiol Dis. 2012;48(3):402-411. " pubmed:22766030". 2012. ↩︎
Wild EJ, Boggio R, Langbehn D, et al. CSF huntingtin fragments as a disease biomarker. J Clin Invest. 2015;125(5):1978-1986. " pubmed:25844897". 2015. ↩︎
Kayed R, Head E, Thompson JL, et al. Soluble oligomer-specific antibodies in neurodegenerative disease. J Mol Neurosci. 2003;20(3):305-313. " pubmed:14501010". 2003. ↩︎
Zheng S, Ghimire B, Ghag G, et al. Phospho-Ser421 huntingtin in brain. J Cell Physiol. 2013;228(7):1430-1437. " pubmed:23255161". 2013. ↩︎
Jacobsen JC, Gregory GC, Wacker DA, et al. PET imaging of mutant huntingtin. Brain. 2010;133(Pt 9):2642-2655. " pubmed:20601636". 2010. ↩︎
Douaud G, Behrens TE, Vandesande P, et al. In vivo MRI of Huntington's disease. Neuroimage. 2009;47(4):1336-1344. " pubmed:19361560". 2009. ↩︎